Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study

Ayong Cao, Jin Zhang, Xiaoan Liu, Weizhu Wu, Yinhua Liu, Zhimin Fan, Anqin Zhang, Tianning Zhou, Peifen Fu, Shu Wang, Quchang Ouyang, Jinhai Tang, Hongchuan Jiang, Xiaohua Zhang, Da Pang, Jianjun He, Linxiang Shi, Xianming Wang, Yuan Sheng, Dahua Mao, Zhimin Shao, Ayong Cao, Jin Zhang, Xiaoan Liu, Weizhu Wu, Yinhua Liu, Zhimin Fan, Anqin Zhang, Tianning Zhou, Peifen Fu, Shu Wang, Quchang Ouyang, Jinhai Tang, Hongchuan Jiang, Xiaohua Zhang, Da Pang, Jianjun He, Linxiang Shi, Xianming Wang, Yuan Sheng, Dahua Mao, Zhimin Shao

Abstract

Background: Estimating quality of life (QoL) in patients with breast cancer is of importance in assessing treatment outcomes. Adjuvant endocrine therapy is widely used for hormone receptor-positive (HR+) early-stage breast cancer (EBC), and evidence suggests that aromatase inhibitors (AIs) may improve QoL for these patients. This study evaluated QoL in postmenopausal Chinese patients with HR+ EBC taking AIs.

Methods: This was a prospective, multicenter, and observational study that had no intent to intervene in the current treatment of recruited patients. Eligible patients were recruited within 7 days of beginning adjuvant treatment with AIs. The Functional Assessment of Cancer Therapy-Breast (FACT-B) scale was used to evaluate the patients' QoL. Data were collected at baseline and at 6, 12, 18, and 24 months.

Results: From June 2010 to October 2013, a total of 494 patients with HR+ EBC were recruited from 21 centers. There was a 7.51-point increase in the patients' mean FACT-B trial outcome index (TOI), from 90.69 at baseline to 98.72 at 24 months (P < .0001). The mean TOI scores at baseline, 6, 12, and 18 months were 90.69, 94.36, 97.71, and 96.75, respectively (P < .0001, for all). The mean (FACT-B) emotional well-being subscale scores at baseline, 6, 12, 18, and 24 months were 16.32, 16.55, 17.34 (P < .0001), 17.47 (P < .0001), and 17.85 (P < .0001), respectively, and social well-being scores were 18.61, 19.14 (P < .04), 19.35 (P < .008), 18.32, and 18.40, respectively. In the mixed model, baseline TOI, clinical visits, prior chemotherapies, age group, and axillary lymph-node dissection presented statistically significant effects on the change of FACT-B TOI and FACT-B SWB, whereas only baseline TOI, clinical visits, and prior chemotherapies presented statistically significant effects on the change of FACT-B EWB. FACT-B TOI, being the most pertinent and precise indicator of patient-reported QoL, demonstrated significant changes reflecting clinical benefit of adjuvant AIs endocrine therapy in the QoL of HR + EBC patients.

Conclusions: The study demonstrated significant improvements in the long-term QoL of postmenopausal Chinese patients with HR+ EBC at 6, 12, 18, and 24 months after starting treatment with AIs. The current study indicates improved long-term QoL with AI adjuvant treatment, which will aid clinicians in optimizing treatment to yield effective healthcare outcomes.

Trial registration: Clinicaltrials.gov NCT01144572.

Keywords: Adjuvant; Aromatase inhibitors; Early breast cancer; Functional Assessment of Cancer Therapy-Breast; Hormone receptor-positive early-stage breast cancer postmenopause; Prospective; Quality of life; Trial outcome index.

Figures

Fig. 1
Fig. 1
Study flow chart

References

    1. Latest world cancer statistics. World Health Organization web site 2015. . Accessed: November 5th 2015.
    1. Fan L, Strasser-Weippl K, Li JJ, St LJ, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. doi: 10.1016/S1470-2045(13)70567-9.
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. doi: 10.1016/S0140-6736(05)66544-0.
    1. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001;31(2–3):233–40. doi: 10.1016/S0169-5002(00)00179-3.
    1. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. How quality of life data contribute to our understanding of cancer patients’ experiences? A study of patients with lung cancer. Qual Life Res. 2003;12(2):157–66. doi: 10.1023/A:1022232624891.
    1. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41. doi: 10.1016/S1470-2045(10)70257-6.
    1. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–8. doi: 10.1016/S1470-2045(11)70270-4.
    1. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014;12(4):542–90.
    1. Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol. 2011;29(12):1531–8. doi: 10.1200/JCO.2010.30.3677.
    1. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32. doi: 10.1186/1756-9966-27-32.
    1. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273–84. doi: 10.1007/s10549-006-9260-6.
    1. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22(21):4261–71. doi: 10.1200/JCO.2004.08.029.
    1. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24(6):910–7. doi: 10.1200/JCO.2005.03.3654.
    1. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931–40. doi: 10.1200/JCO.2005.11.181.
    1. Shen FR, Liu M, Zhang X, Feng YH, Zhou LS, Chen YG. Health-related quality of life among breast cancer patients and its influencing factor in a Chinese population. Asian Pac J Cancer Prev. 2012;13(8):3747–50. doi: 10.7314/APJCP.2012.13.8.3747.
    1. Buijs C, de Vries EG, Mourits MJ, Willemse PH. The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev. 2008;34(7):640–55. doi: 10.1016/j.ctrv.2008.04.001.
    1. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.
    1. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55(3):285–95. doi: 10.1016/S0895-4356(01)00477-2.
    1. Kwan ML, Ergas IJ, Somkin CP, Quesenberry CP, Jr, Neugut AI, Hershman DL, et al. Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study. Breast Cancer Res Treat. 2010;123(2):507–24. doi: 10.1007/s10549-010-0764-8.
    1. Claudat K, Warren CS, Durette RT. The relationships between body surveillance, body shame, and contextual body concern during sexual activities in ethnically diverse female college students. Body Image. 2012;9(4):448–54. doi: 10.1016/j.bodyim.2012.05.007.
    1. Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006;15(7):579–94. doi: 10.1002/pon.991.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅